World Health Organization‐defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management

American Journal of Hematology - Tập 87 Số 9 - Trang 903-914 - 2012
Jason Gotlib1
1Division of Hematology, Stanford University Medical Center, Palo Alto, California

Tóm tắt

AbstractDisease overview: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end‐organ damage.Diagnosis: Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1,500/mm3 and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of morphologic review of the blood and marrow, standard cytogenetics, fluorescent in situ‐hybridization, flow immunocytometry, and T‐cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic myeloid or lymphoproliferative disorder.Risk stratification: Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2008 World Health Organization establishes a semimolecular classification scheme of disease subtypes including “myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1,” chronic eosinophilic leukemia, not otherwise specified' (CEL, NOS), lymphocyte‐variant hypereosinophilia, and idiopathic hypereosinophilic syndrome (HES), which is a diagnosis of exclusion.Risk‐adapted therapy: The goal of therapy is to mitigate eosinophil‐mediated organ damage. For patients with milder forms of eosinophilia (e.g., <1,500/mm3) without symptoms or signs of organ involvement, a watch and wait approach with close‐follow‐up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Corticosteroids are first‐line therapy for patients with lymphocyte‐variant hypereosinophilia and HES. Hydroxyurea and interferon‐alpha have demonstrated efficacy as initial treatment and steroid‐refractory cases of HES. In addition to hydroxyurea, second line cytotoxic chemotherapy agents and hematopoietic cell transplant have been used for aggressive forms of HES and CEL with outcomes reported for limited numbers of patients. Although clinical trials have been performed with anti IL‐5 (mepolizumab) and anti‐CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/j.jaci.2010.03.035

10.1038/leu.2008.287

10.1182/blood-2006-10-050054

10.1182/blood-2004-03-0787

10.1016/j.leukres.2005.11.011

10.1016/S0022-3476(87)80352-9

10.1097/00043426-200301000-00017

10.1097/01.mph.0000193467.06938.77

10.1056/NEJMoa025217

10.3324/haematol.11420

Brigden M, 1997, Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance, Arch Pathol Lab Med, 121, 963

10.1056/NEJM199805283382206

10.1111/j.1365-2141.2006.06038.x

Bain BJ, 2008, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 68

Bain BJ, 2008, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 51

10.1097/00005792-197501000-00001

10.1016/j.jaci.2012.02.019

10.7326/0003-4819-97-1-78

10.1016/j.jaci.2009.09.022

Spry CJ, 1983, Clinical features of fifteen patients with the hypereosinophilic syndrome, Q J Med, 52, 1

Lefebvre C, 1989, Prognostic factors of hypereosinophilic syndrome. Study of 40 cases, Ann Med Interne (Paris), 140, 253

10.1182/blood.V58.5.1012.1012

10.1182/blood-2003-06-1824

10.1182/blood.V83.10.2759.2759

Tanino M, 1983, Hypereosinophilic syndrome with extensive myocardial involvement and mitral valve thrombus instead of mural thrombi, Acta Pathol Jpn, 33, 1233

10.1017/S1047951102000136

10.1016/S0002-9149(00)00841-9

10.1111/j.1365-4632.2008.03637.x

10.1590/S1806-37132009000600010

10.1007/s10620-005-9011-2

10.1177/030089169107700616

10.1007/BF01697986

10.1111/j.1365-2141.1980.tb07174.x

10.1182/blood-2003-05-1627

10.1182/blood-2003-01-0006

10.1038/sj.leu.2404662

10.1182/blood-2010-05-286757

10.1016/j.cancergencyto.2004.01.013

10.1038/ng0198-84

10.1182/blood.V92.5.1735

10.1073/pnas.95.10.5712

10.1093/hmg/7.4.637

10.1056/NEJM199910073411503

10.1111/j.1398-9995.2004.00465.x

10.1056/NEJM199402243300804

10.1084/jem.183.3.1071

10.1182/blood.V87.4.1416.bloodjournal8741416

10.1182/blood.V94.3.994.415k26_994_1002

10.3109/10428190109097684

10.3324/haematol.2009.010421

10.3324/haematol.2008.005447

10.1067/mai.2002.127003

10.1002/ajh.23193

10.1038/sj.leu.2400839

10.1046/j.1365-2141.2000.02097.x

10.3109/10428199709059688

10.1182/blood-2009-05-220145

10.1002/cncr.25036

10.1182/blood-2002-03-0947

Ackerman SJ, 2005, Hematology

10.1046/j.1365-2141.2003.04195.x

Schaller JL, 2001, Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate, MedGenMed, 3, 9

10.1016/S0140-6736(02)08505-7

10.1016/S0145-2126(02)00046-2

10.1073/pnas.0932698100

10.1182/blood-2003-08-2798

10.1111/j.1365-2141.2008.07033.x

10.1182/blood-2007-07-100164

10.1038/sj.leu.2403600

10.1111/j.1365-2141.2006.06221.x

10.1038/leu.2009.2

10.1182/blood-2006-02-004580

10.1016/S1535-6108(03)00108-9

10.1182/blood-2006-02-004457

10.1182/blood-2005-05-1932

10.1182/blood-2006-01-0285

10.1038/leu.2011.181

10.1016/j.jaci.2007.11.027

10.1182/blood-2006-05-024828

10.1073/pnas.0404438101

10.1158/0008-5472.CAN-04-4263

10.1038/sj.leu.2404266

10.1182/blood-2002-10-3103

10.1182/blood-2003-07-2393

10.7326/0003-4819-89-2-167

10.1182/blood.V85.8.2284.bloodjournal8582284

Luciano L, 1999, αIFN–induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5), Haematologica, 84, 651

10.1002/(SICI)1096-8652(199806)58:2<137::AID-AJH9>3.0.CO;2-T

10.1046/j.1365-2141.1996.00298.x

10.1016/0091-6749(94)90348-4

10.1007/s002770050434

10.1111/j.1346-8138.2000.tb02131.x

10.1159/000085560

10.1002/cncr.23018

10.1182/blood-2008-03-143537

10.1200/JCO.2009.23.6075

10.1016/0002-9343(75)90368-X

10.1159/000206350

10.1097/00043426-199211000-00012

10.3349/ymj.2002.43.2.267

10.1002/1097-0142(19910601)67:11<2826::AID-CNCR2820671119>3.0.CO;2-#

10.7326/0003-4819-121-11-199412010-00022

10.1038/sj.leu.2400717

10.1002/cncr.21186

10.1007/BF01729838

10.1542/peds.99.4.630

10.1016/j.leukres.2008.12.001

Helbig G, 2011, Imatinib mesylate may induce long‐term clinical response in FIP1L1‐PDGFRα‐negative hypereosinophilic syndrome, Med Onc

10.1067/mai.2001.116576

10.1056/NEJMoa031261

10.1016/j.jaci.2003.10.049

10.1182/blood-2003-10-3620

10.1056/NEJMoa070812

Walsh GM, 2009, Reslizumab, a humanized anti‐IL‐5 mAb for the treatment of eosinophil‐mediated inflammatory conditions, Curr Opin Mol Ther, 11, 329

10.1016/j.jaci.2011.11.044

10.1182/blood-2005-08-3153

10.1111/j.1365-2141.2004.05206.x

10.1046/j.1365-2141.2003.04801.x

10.1158/1078-0432.CCR-08-1302

10.1038/sj.bmt.1702102

10.1038/sj.bmt.1701783

10.3109/10428199809059261

Sigmund DA, 1995, Hypereosinophilic syndrome: Successful allogeneic bone marrow transplantation, Bone Marrow Transplant, 15, 647

10.1002/(SICI)1096-8652(199602)51:2<164::AID-AJH12>3.0.CO;2-I

10.1038/sj.bmt.1700729

10.1038/sj.bmt.1703379

10.1046/j.1365-2141.2002.03771.x

10.1038/sj.bmt.1705437

10.7326/0003-4819-91-4-650_2

10.7326/0003-4819-96-6-791_1

Chambers LA, 1990, Management of hypereosinophilic syndrome with chronic plasma‐ and leukapheresis, Prog Clin Biol Res, 337, 83

10.1046/j.1365-2133.2003.05309.x

10.7326/0003-4819-102-1-109

10.1177/014107689809100912

10.1017/S1047951102000136

10.1016/0002-9343(82)90929-9

10.1016/S0003-4975(10)64701-7

10.5694/j.1326-5377.1985.tb123104.x

10.1111/j.1540-8191.2008.00639.x

10.1016/S0003-4975(96)00947-2

10.1182/blood-2005-03-1320

10.3324/haematol.11841

10.1002/eji.1830271256

10.1002/jlb.65.5.700

10.1371/journal.pone.0034912

10.3324/haematol.2011.047530

Thông tin
Thông tin xuất bản

American Journal of Hematology

Tập 87 Số 9

903-914

Thông tin tác giả